{{expand|time=2015-09-29T11:04:28+00:00}}
{{medical}}

'''5-羟色胺、去甲肾上腺素和多巴胺再摄取抑制剂'''（{{lang-en|'''serotonin–norepinephrine–dopamine reuptake inhibitor'''}}，'''SNDRI'''），也称作'''三重再摄取抑制剂'''（'''TRI'''），是多种[[单胺|单胺]]类[[神经递质|神经递质]]的[[再摄取抑制剂|再摄取抑制剂]]，原理为通过抑制[[5-羟色胺转运体|5-羟色胺转运体]]、[[去甲肾上腺素转运体|去甲肾上腺素转运体]]和[[多巴胺转运体|多巴胺转运体]]体来分别抑制[[5-羟色胺|5-羟色胺]]、 [[去甲肾上腺素|去甲肾上腺素]]和[[多巴胺|多巴胺]]的再摄取。这个作用会增加这些神经递质在突触间隙的浓度。

SNDRI作為一系列疾病的[[药学|藥物]]候選而被開發，如[[抗抑郁药|抗憂鬱劑]]<ref name="Musk">{{Cite journal|pmid=20704963|year=2004|last1=Musk|first1=P|title=Magic shotgun methods for developing drugs for CNS disorders|volume=4|issue=23|pages=299–302|journal=Discovery medicine}}</ref><ref name="Millan2">{{Cite journal|pmid=19110199|year=2009|last1=Millan|first1=MJ|title=Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: Novel concepts, new drugs|volume=6|issue=1|pages=53–77|doi=10.1016/j.nurt.2008.10.039|journal=Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics}}</ref><ref name="Chen">{{Cite journal|pmid=17714023|year=2007|last1=Chen|first1=Z|last2=Skolnick|first2=P|title=Triple uptake inhibitors: Therapeutic potential in depression and beyond|volume=16|issue=9|pages=1365–77|doi=10.1517/13543784.16.9.1365|journal=Expert Opinion on Investigational Drugs}}</ref><ref name="Perona">{{Cite journal| pmid=18690111|year=2008|last1=Perona|first1=MT|last2=Waters|first2=S|last3=Hall|first3=FS|last4=Sora|first4=I|last5=Lesch|first5=KP|last6=Murphy|first6=DL|last7=Caron|first7=M|last8=Uhl|first8=GR|title=Animal models of depression in dopamine, serotonin, and norepinephrine transporter knockout mice: Prominent effects of dopamine transporter deletions|volume=19|issue=5–6|pages=566–74|doi=10.1097/FBP.0b013e32830cd80f|pmc=2644662|journal=Behavioural Pharmacology}}</ref><ref name="Chen2">{{Cite journal|pmid=18311656|year=2008|last1=Chen|first1=Z|last2=Yang|first2=J|last3=Tobak|first3=A|title=Designing new treatments for depression and anxiety|volume=11|issue=3|pages=189–97|journal=IDrugs : the investigational drugs journal}}</ref>
和治療[[肥胖症|肥胖]]、[[可卡因|古柯鹼成癮]]、[[注意力不足過動症|注意力缺陷/過動症]](ADHD)及[[慢性疼痛|慢性疼痛]]的藥物。SNDRI作為[[選擇性血清素再吸收抑制劑|選擇性血清素再吸收抑制劑]](SSRIs)及[[血清素-去甲腎上腺素再吸收抑制劑|血清素-去甲腎上腺素再吸收抑制劑]](SNRIs)的延伸，增加了[[多巴胺|多巴胺]]的[[再吸收抑制劑|再吸收抑制]]作用，這被認為具有增加療效的可能，但[[副作用|副作用]]及[[物質濫用|藥物濫用]]的可能也隨之增加。

==引用==
{{reflist}}

{{抗抑鬱藥|RARIs}}

[[Category:再摄取抑制剂|Category:再摄取抑制剂]]
[[Category:血清素-去甲肾上腺素-多巴胺重摄取抑制剂|Category:血清素-去甲肾上腺素-多巴胺重摄取抑制剂]]